Mark Levis, MD, PhD, explains the key factors influencing 1st line therapy in acute myeloid leukemia(AML) patients with FLT3 mutations at Annual Meeting 2018.
1st line therapy in AML patients with FLT3 mutations
Advertisement
[the_ad id="32629"]